BACKGROUND: CD4(+)CD25(+) regulatory T cells can inhibit excessive T-cell responses in vivo. We have previously demonstrated that prophylactic administration of CD4(+)CD25(+) regulatory T cells suppresses the development of acute allergen-induced airway inflammation in vivo. OBJECTIVE: We sought to determine the effect of therapeutic transfer of CD4(+)CD25(+) regulatory T cells on established pulmonary inflammation and the subsequent development of airway remodeling. METHODS: CD4(+)CD25(+) cells were transferred after the onset of allergic inflammation, and airway challenges were continued to induce chronic inflammation and airway remodeling. RESULTS: Administration of CD4(+)CD25(+) regulatory T cells reduced established lung eosinophilia, T(H)2 infiltration, and expression of IL-5, IL-13, and TGF-beta. Moreover, subsequent mucus hypersecretion and peribronchial collagen deposition were reduced after prolonged challenge. In contrast, transfer of CD4(+)CD25(+) regulatory T cells had no effect on established airway hyperreactivity either 7 days or 4 weeks after transfer. CONCLUSIONS: In this study we demonstrate for the first time that therapeutic transfer of CD4(+)CD25(+) regulatory T cells can resolve features of chronic allergen-induced inflammation and prevent development of airway remodeling.
BACKGROUND:CD4(+)CD25(+) regulatory T cells can inhibit excessive T-cell responses in vivo. We have previously demonstrated that prophylactic administration of CD4(+)CD25(+) regulatory T cells suppresses the development of acute allergen-induced airway inflammation in vivo. OBJECTIVE: We sought to determine the effect of therapeutic transfer of CD4(+)CD25(+) regulatory T cells on established pulmonary inflammation and the subsequent development of airway remodeling. METHODS:CD4(+)CD25(+) cells were transferred after the onset of allergic inflammation, and airway challenges were continued to induce chronic inflammation and airway remodeling. RESULTS: Administration of CD4(+)CD25(+) regulatory T cells reduced established lung eosinophilia, T(H)2 infiltration, and expression of IL-5, IL-13, and TGF-beta. Moreover, subsequent mucus hypersecretion and peribronchial collagen deposition were reduced after prolonged challenge. In contrast, transfer of CD4(+)CD25(+) regulatory T cells had no effect on established airway hyperreactivity either 7 days or 4 weeks after transfer. CONCLUSIONS: In this study we demonstrate for the first time that therapeutic transfer of CD4(+)CD25(+) regulatory T cells can resolve features of chronic allergen-induced inflammation and prevent development of airway remodeling.
Authors: Ruth H Green; Christopher E Brightling; Susan McKenna; Beverley Hargadon; Debbie Parker; Peter Bradding; Andrew J Wardlaw; Ian D Pavord Journal: Lancet Date: 2002-11-30 Impact factor: 79.321
Authors: John F Alcorn; Lisa M Rinaldi; Elizabeth F Jaffe; Mirjam van Loon; Jason H T Bates; Yvonne M W Janssen-Heininger; Charles G Irvin Journal: Am J Respir Crit Care Med Date: 2007-08-29 Impact factor: 21.405
Authors: C M Lloyd; J A Gonzalo; T Nguyen; T Delaney; J Tian; H Oettgen; A J Coyle; J C Gutierrez-Ramos Journal: J Immunol Date: 2001-02-01 Impact factor: 5.422
Authors: Patrick Flood-Page; Andrew Menzies-Gow; Simon Phipps; Sun Ying; Arun Wangoo; Mara S Ludwig; Neil Barnes; Douglas Robinson; A Barry Kay Journal: J Clin Invest Date: 2003-10 Impact factor: 14.808
Authors: C G Lee; R J Homer; Z Zhu; S Lanone; X Wang; V Koteliansky; J M Shipley; P Gotwals; P Noble; Q Chen; R M Senior; J A Elias Journal: J Exp Med Date: 2001-09-17 Impact factor: 14.307
Authors: A Iellem; M Mariani; R Lang; H Recalde; P Panina-Bordignon; F Sinigaglia; D D'Ambrosio Journal: J Exp Med Date: 2001-09-17 Impact factor: 14.307
Authors: Carissa M Krane; Bijia Deng; Venkateshwar Mutyam; Casey A McDonald; Stephen Pazdziorko; Lawrence Mason; Samuel Goldman; Marion Kasaian; Divya Chaudhary; Cara Williams; Melisa W Y Ho Journal: Cytokine Date: 2009-02-23 Impact factor: 3.861